Johansen T - Search Results

1

Measurement of free GH and bioactive IGF-I in non-diabetic haemodialysis patients treated with GH for 7 days.

Frystyk J, Djurhuus CB, Johansen T, Lange M, Smidt K, Christiansen JS. Frystyk J, et al. Among authors: johansen t. Nephrol Dial Transplant. 2012 Nov;27(11):4211-8. doi: 10.1093/ndt/gfs364. Epub 2012 Aug 21. Nephrol Dial Transplant. 2012. PMID: 22910041

2

Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.

Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G. Christiansen JS, et al. Among authors: johansen t. J Diabetes. 2016 Sep;8(5):720-8. doi: 10.1111/1753-0407.12355. Epub 2016 Mar 6. J Diabetes. 2016. PMID: 26612062

3

Reduction of adiposity with prolonged growth hormone treatment in old obese rats: effects on glucose handling and early insulin signaling.

Johansen T, Laurino C, Barreca A, Malmlöf K. Johansen T, et al. Growth Horm IGF Res. 2005 Feb;15(1):55-63. doi: 10.1016/j.ghir.2004.11.006. Epub 2005 Jan 22. Growth Horm IGF Res. 2005. PMID: 15701573

4

Treatment of Obesity Using GH.

Johansen T, Malmlöf K. Johansen T, et al. Metab Syndr Relat Disord. 2006 Spring;4(1):57-69. doi: 10.1089/met.2006.4.57. Metab Syndr Relat Disord. 2006. PMID: 18370772

5

The obese Göttingen minipig as a model of the metabolic syndrome: dietary effects on obesity, insulin sensitivity, and growth hormone profile.

Johansen T, Hansen HS, Richelsen B, Malmlöf R. Johansen T, et al. Comp Med. 2001 Apr;51(2):150-5. Comp Med. 2001. PMID: 11922179

6

Growth hormone-mediated breakdown of body fat: insulin and leptin responses to GH are modulated by diet composition and caloric intake in old rats.

Malmlöf K, Johansen T. Malmlöf K, et al. Among authors: johansen t. Horm Metab Res. 2003 Apr;35(4):236-42. doi: 10.1055/s-2003-39480. Horm Metab Res. 2003. PMID: 12778367

7

The role of growth hormone and glucocorticoid in glucose handling in vivo.

Johansen T, Deckert M, Mandrup-Poulsen T, Malmlöf K. Johansen T, et al. J Endocrinol. 1999 Jul;162(1):87-93. doi: 10.1677/joe.0.1620087. J Endocrinol. 1999. PMID: 10396024

8

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials.

Vora J, Seufert J, Solberg H, Kinduryte O, Johansen T, Hollander P. Vora J, et al. Among authors: johansen t. Diabetes Obes Metab. 2016 Jul;18(7):716-20. doi: 10.1111/dom.12621. Epub 2016 Feb 8. Diabetes Obes Metab. 2016. PMID: 26663320 Free PMC article.

9

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Zinman B, et al. Among authors: johansen t. Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7. Lancet. 2011. PMID: 21396703 Clinical Trial.

10

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R; NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators. Zinman B, et al. Among authors: johansen t. Lancet Diabetes Endocrinol. 2013 Oct;1(2):123-31. doi: 10.1016/S2213-8587(13)70013-5. Epub 2013 Jul 9. Lancet Diabetes Endocrinol. 2013. PMID: 24622318 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

792 results

Search Page